EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies

Pei Lin, Yunfan Lin, Zizhao Mai, Yucheng Zheng, Jiarong Zheng, Zihao Zhou, Xinyuan Zhao, Li Cui

Theranostics · 01.01.2025 · 15 (1) · 300-323

DOI: 10.7150/thno.104594 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Theranostics, erschienen am 01.01.2025. Verfasst von Pei Lin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China. Hauptthemen laut MEDLINE: Neoplasms, Receptors, Antigen, T-Cell, T-Lymphocytes. Die Arbeit wurde bisher 33-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T cell receptor-engineered T (TCR-T) cell therapies are at the forefront of cancer immunotherapy, offering a transformative approach that significantly enhances the ability of T cells to recognize and eliminate cancer cells. This innovative method involves genetically modifying TCRs to increase their affinity for tumor-specific antigens. While these enhancements improve the ability of T cells to recognize and bind to antigens on cancer cells, rigorous assessment of specificity remains crucial to ensure safety and targeted responses. This dual focus on affinity and specificity holds significant promise for the treatment of solid tumors, enabling precise and efficient cancer cell recognition. Despite rapid advancements in TCR engineering and notable progress in TCR screening technologies, as evidenced by the growing number of specific TCRs entering clinical trials, several technical and clinical challenges remain. These challenges primarily pertain to the specificity, affinity, and safety of engineered TCRs. Moreover, the accurate identification and selection of TCRs that are both effective and safe are essential for the success of TCR-T cell therapies in cancer treatment. This review provides a comprehensive examination of the theoretical foundations of TCR therapy, explores strategies for screening specific TCRs and antigens, and highlights the ongoing challenges in this evolving therapeutic landscape.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsReceptors, Antigen, T-CellT-LymphocytesHumansAntigens, NeoplasmImmunotherapy, AdoptiveAnimalsImmunotherapy

Stichwörter der Autor:innen

T cell receptor-engineered T cell therapycancer immunotherapyscreening strategy

Substanzen

Receptors, Antigen, T-CellAntigens, Neoplasm

Autor:innen und Institutionen

  • Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China.
  • Department of Dentistry, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, 510080, China.
  • School of Dentistry, University of California, Los Angeles, Los Angeles, 90095, CA, USA.

Zitieren

APA

Lin, P., Lin, Y., Mai, Z., Zheng, Y., Zheng, J., Zhou, Z., Zhao, X., & Cui, L. (2025). Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies. Theranostics, 15(1), 300-323. https://doi.org/10.7150/thno.104594

Vancouver

Lin P, Lin Y, Mai Z, Zheng Y, Zheng J, Zhou Z, et al. Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies. Theranostics. 2025;15(1):300-323. doi:10.7150/thno.104594

BibTeX
@article{Lin2025,
  author = {Lin, Pei and Lin, Yunfan and Mai, Zizhao and Zheng, Yucheng and Zheng, Jiarong and Zhou, Zihao and Zhao, Xinyuan and Cui, Li},
  title = {Targeting cancer with precision: strategical insights into TCR-engineered T cell therapies},
  journal = {Theranostics},
  year = {2025},
  volume = {15},
  number = {1},
  pages = {300--323},
  doi = {10.7150/thno.104594}
}
Kostenlos starten →